ArticleJournal of the Endocrine Society2025
Cardiometabolic Risk Factors and Adverse Outcomes in Pregnant Women With Type 2 Diabetes.
Article in Journal of the Endocrine Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Obstetrical and medical outcomes following GLP-1 receptor agonist exposure in pregnancy: a case series.Case reports in women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: The prevalence of type 2 diabetes (T2DM) in pregnancy is increasing rapidly worldwide. Consequently, there is a need to gain more knowledge about pregnant women with T2DM. Objective: The current study aimed to assess the prevalence of cardiometabolic risk factors and comorbidities in women with T2DM before and during pregnancy, and to evaluate associations with adverse obstetric and perinatal outcomes. A comparison between women with preexisting T2DM (P-T2DM) and women with T2DM first recognized during pregnancy (N-T2DM) was also performed. Design: A retrospective Danish national population-based cohort study, including all pregnancies in women with T2DM, giving birth to a live infant after 24 weeks of gestation, from 2004 until 2019. Results: The population included 1297 pregnancies in women with T2DM (1207 P-T2DM, 90 N-T2DM). Before pregnancy, 20.4% smoked, 13.4% had chronic hypertension, 12.5% had dyslipidemia, and 63.1% had obesity. Only 58.6% of women with P-T2DM entered pregnancy with hemoglobin A1c (HbA1c) < 53 mmol/mol (7.0%). During pregnancy, 73.4% had an excessive weight gain, and 21.6% attained a median HbA1c < 38 mmol/mol (5.6%). Preeclampsia was observed in 9.1% of women, preterm delivery in 19.0%, and large-for-gestational-age birthweight in 32.2% of infants. Obstetric and perinatal outcomes were similar in women with P-T2DM and N-T2DM. All modifiable exposures were associated with one or more severe adverse outcomes. Conclusion: Cardiometabolic risk factors are prevalent in pregnant women with T2DM and are associated with severe adverse outcomes for mother and child.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.